92
Participants
Start Date
October 31, 2007
Primary Completion Date
January 31, 2008
Study Completion Date
January 31, 2008
PD 0200390
oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
PD 0200390
oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
PD 0200390
oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
PD 0200390
oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
Placebo
oral placebo mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
Pfizer Investigational Site, New York
Pfizer Investigational Site, Cary
Pfizer Investigational Site, Raleigh
Pfizer Investigational Site, Atlanta
Pfizer Investigational Site, Atlanta
Pfizer Investigational Site, Miami
Pfizer Investigational Site, South Miami
Pfizer Investigational Site, Naples
Pfizer Investigational Site, Crestview Hills
Pfizer Investigational Site, Cincinnati
Pfizer Investigational Site, Overland Park
Pfizer Investigational Site, Phenoix
Pfizer Investigational Site, Phoenix
Pfizer Investigational Site, Glendale
Pfizer Investigational Site, Tucson
Pfizer Investigational Site, San Diego
Lead Sponsor
Pfizer
INDUSTRY